Current Landscape of Immunotherapy in Breast Cancer

A Review

Sylvia Adams, Margaret E. Gatti-Mays, Kevin Kalinsky, Larissa A. Korde, Elad Sharon, Laleh Amiri-Kordestani, Harry Bear, Heather L. McArthur, Elizabeth Frank, Jane Perlmutter, David B. Page, Benjamin Vincent, Jennifer F. Hayes, James L. Gulley, Jennifer K. Litton, Gabriel N. Hortobagyi, Stephen Chia, Ian Krop, Julia White, Joseph A. Sparano & 2 others Mary L. Disis, Elizabeth A. Mittendorf

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Importance: There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. Observations: After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. Conclusions and Relevance: It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.

Original languageEnglish (US)
JournalJAMA Oncology
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Immunotherapy
Breast Neoplasms
Active Immunotherapy
Tumor Microenvironment
Secondary Prevention
Combination Drug Therapy
PubMed
Therapeutics
Biomarkers
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., ... Mittendorf, E. A. (2019). Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.7147

Current Landscape of Immunotherapy in Breast Cancer : A Review. / Adams, Sylvia; Gatti-Mays, Margaret E.; Kalinsky, Kevin; Korde, Larissa A.; Sharon, Elad; Amiri-Kordestani, Laleh; Bear, Harry; McArthur, Heather L.; Frank, Elizabeth; Perlmutter, Jane; Page, David B.; Vincent, Benjamin; Hayes, Jennifer F.; Gulley, James L.; Litton, Jennifer K.; Hortobagyi, Gabriel N.; Chia, Stephen; Krop, Ian; White, Julia; Sparano, Joseph A.; Disis, Mary L.; Mittendorf, Elizabeth A.

In: JAMA Oncology, 01.01.2019.

Research output: Contribution to journalReview article

Adams, S, Gatti-Mays, ME, Kalinsky, K, Korde, LA, Sharon, E, Amiri-Kordestani, L, Bear, H, McArthur, HL, Frank, E, Perlmutter, J, Page, DB, Vincent, B, Hayes, JF, Gulley, JL, Litton, JK, Hortobagyi, GN, Chia, S, Krop, I, White, J, Sparano, JA, Disis, ML & Mittendorf, EA 2019, 'Current Landscape of Immunotherapy in Breast Cancer: A Review', JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.7147
Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L et al. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncology. 2019 Jan 1. https://doi.org/10.1001/jamaoncol.2018.7147
Adams, Sylvia ; Gatti-Mays, Margaret E. ; Kalinsky, Kevin ; Korde, Larissa A. ; Sharon, Elad ; Amiri-Kordestani, Laleh ; Bear, Harry ; McArthur, Heather L. ; Frank, Elizabeth ; Perlmutter, Jane ; Page, David B. ; Vincent, Benjamin ; Hayes, Jennifer F. ; Gulley, James L. ; Litton, Jennifer K. ; Hortobagyi, Gabriel N. ; Chia, Stephen ; Krop, Ian ; White, Julia ; Sparano, Joseph A. ; Disis, Mary L. ; Mittendorf, Elizabeth A. / Current Landscape of Immunotherapy in Breast Cancer : A Review. In: JAMA Oncology. 2019.
@article{231fef2c206849fea35d2b150ede876d,
title = "Current Landscape of Immunotherapy in Breast Cancer: A Review",
abstract = "Importance: There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. Observations: After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. Conclusions and Relevance: It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.",
author = "Sylvia Adams and Gatti-Mays, {Margaret E.} and Kevin Kalinsky and Korde, {Larissa A.} and Elad Sharon and Laleh Amiri-Kordestani and Harry Bear and McArthur, {Heather L.} and Elizabeth Frank and Jane Perlmutter and Page, {David B.} and Benjamin Vincent and Hayes, {Jennifer F.} and Gulley, {James L.} and Litton, {Jennifer K.} and Hortobagyi, {Gabriel N.} and Stephen Chia and Ian Krop and Julia White and Sparano, {Joseph A.} and Disis, {Mary L.} and Mittendorf, {Elizabeth A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2018.7147",
language = "English (US)",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Current Landscape of Immunotherapy in Breast Cancer

T2 - A Review

AU - Adams, Sylvia

AU - Gatti-Mays, Margaret E.

AU - Kalinsky, Kevin

AU - Korde, Larissa A.

AU - Sharon, Elad

AU - Amiri-Kordestani, Laleh

AU - Bear, Harry

AU - McArthur, Heather L.

AU - Frank, Elizabeth

AU - Perlmutter, Jane

AU - Page, David B.

AU - Vincent, Benjamin

AU - Hayes, Jennifer F.

AU - Gulley, James L.

AU - Litton, Jennifer K.

AU - Hortobagyi, Gabriel N.

AU - Chia, Stephen

AU - Krop, Ian

AU - White, Julia

AU - Sparano, Joseph A.

AU - Disis, Mary L.

AU - Mittendorf, Elizabeth A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. Observations: After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. Conclusions and Relevance: It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.

AB - Importance: There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. Observations: After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. Conclusions and Relevance: It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.

UR - http://www.scopus.com/inward/record.url?scp=85064259674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064259674&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.7147

DO - 10.1001/jamaoncol.2018.7147

M3 - Review article

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -